BACKGROUND: Normalization of IGF-I in patients with acromegaly is associated with a decrease in mortality. Pegvisomant may be more effective in lowering IGF-I than octreotide. SUBJECTS AND METHODS: The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study. The primary endpoint was IGF-I normalization at week 52. Secondary endpoints included mean changes from baseline in IGF-I, IGF binding protein 3, acromegaly signs and symptom scores, ring size, acromegaly quality of life questionnaire scores, and safety. RESULTS: Fifty-six patients received pegvisomant and 57 received octreotide LAR. IGF-I normalized in 51% of pegvisomant patients and 34% treated with octreotide LAR (p=0.09, ns). Patients with baseline IGF-I > or = 2x upper limit of normal had a higher rate of IGF-I normalization with pegvisomant vs octreotide LAR (p=0.05). Among the patients who did not achieve a normalized IGF-I, pegvisomant-treated patients were more likely to be receiving < 30 mg of study drug (71% vs 16%). Treatment-related adverse events were mild-to-moderate in both groups. Mean fasting glucose decreased in diabetic and non-diabetic patients on pegvisomant whereas octreotide LAR was associated with an increase at week 52 (p=0.005 and p=0.003 between groups, respectively). Mean change in tumor volume during treatment was similar between groups. CONCLUSIONS:Pegvisomant and octreotide LAR were equally effective in normalizing IGF-I in the overall population, and pegvisomant was more effective in patients with higher baseline IGF-I levels. Pegvisomant had a more favorable effect on parameters of glycemic control.
RCT Entities:
BACKGROUND: Normalization of IGF-I in patients with acromegaly is associated with a decrease in mortality. Pegvisomant may be more effective in lowering IGF-I than octreotide. SUBJECTS AND METHODS: The efficacy and safety of pegvisomant and octreotidelong-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study. The primary endpoint was IGF-I normalization at week 52. Secondary endpoints included mean changes from baseline in IGF-I, IGF binding protein 3, acromegaly signs and symptom scores, ring size, acromegaly quality of life questionnaire scores, and safety. RESULTS: Fifty-six patients received pegvisomant and 57 received octreotide LAR. IGF-I normalized in 51% of pegvisomantpatients and 34% treated with octreotide LAR (p=0.09, ns). Patients with baseline IGF-I > or = 2x upper limit of normal had a higher rate of IGF-I normalization with pegvisomant vs octreotide LAR (p=0.05). Among the patients who did not achieve a normalized IGF-I, pegvisomant-treated patients were more likely to be receiving < 30 mg of study drug (71% vs 16%). Treatment-related adverse events were mild-to-moderate in both groups. Mean fasting glucose decreased in diabetic and non-diabeticpatients on pegvisomant whereas octreotide LAR was associated with an increase at week 52 (p=0.005 and p=0.003 between groups, respectively). Mean change in tumor volume during treatment was similar between groups. CONCLUSIONS:Pegvisomant and octreotide LAR were equally effective in normalizing IGF-I in the overall population, and pegvisomant was more effective in patients with higher baseline IGF-I levels. Pegvisomant had a more favorable effect on parameters of glycemic control.
Authors: S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina Journal: Eur J Endocrinol Date: 2005-12 Impact factor: 6.664
Authors: A Colao; G Arnaldi; P Beck-Peccoz; S Cannavò; R Cozzi; E degli Uberti; L De Marinis; E De Menis; D Ferone; V Gasco; A Giustina; S Grottoli; G Lombardi; P Maffei; E Martino; F Minuto; R Pivonello; E Ghigo Journal: J Endocrinol Invest Date: 2007-09 Impact factor: 4.256
Authors: A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner Journal: Lancet Date: 2001-11-24 Impact factor: 79.321
Authors: Shlomo Melmed; Richard Sternberg; David Cook; Anne Klibanski; Philippe Chanson; Vivien Bonert; Mary Lee Vance; David Rhew; David Kleinberg; Ariel Barkan Journal: J Clin Endocrinol Metab Date: 2005-04-12 Impact factor: 5.958
Authors: A K Fløgstad; J Halse; S Bakke; I Lancranjan; P Marbach; C Bruns; J Jervell Journal: J Clin Endocrinol Metab Date: 1997-01 Impact factor: 5.958
Authors: Ariel L Barkan; Pia Burman; David R Clemmons; William M Drake; Robert F Gagel; Philip E Harris; Peter J Trainer; Aart Jan van der Lely; Mary Lee Vance Journal: J Clin Endocrinol Metab Date: 2005-08-02 Impact factor: 5.958
Authors: B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas Journal: J Clin Endocrinol Metab Date: 1998-10 Impact factor: 5.958
Authors: Cornelie D Andela; Margreet Scharloo; Alberto M Pereira; Ad A Kaptein; Nienke R Biermasz Journal: Pituitary Date: 2015-10 Impact factor: 4.107
Authors: S Cannavo; F Bogazzi; A Colao; L De Marinis; P Maffei; R Gomez; E Graziano; M Monterubbianesi; S Grottoli Journal: J Endocrinol Invest Date: 2015-04-28 Impact factor: 4.256
Authors: Laura E Dichtel; Allison Kimball; Kevin C J Yuen; Whitney Woodmansee; Melanie S Haines; Qiu Xia Guan; Brooke Swearingen; Lisa B Nachtigall; Nicholas A Tritos; Julie L Sharpless; Ursula B Kaiser; Anu V Gerweck; Karen K Miller Journal: Clin Endocrinol (Oxf) Date: 2020-09-11 Impact factor: 3.523